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Abstract 
Novel Coronavirus (COVID-19) is a new strain of coronavirus that may cause 
illness in animals or humans. SARS-CoV-2 was first identified in late December 
2019, in Wuhan, China. The coronavirus infected patients ‘who suffering from 
Immundeficient or chronic inflammation are at higher risk of getting a severe 
infection from COVID-19. The symptoms such as proinflammatory and 
hypercoagulable, non-cardiac pneumonia, multi-organ failure, and ARDS 
resulting in sudden death have been seen in those patients. Supportive treatment 
is still the main strategy in treating this disease since there is no evidence that 
current medicine can prevent or cure the infection resulting from coronavirus. 
However, more investigations are needed to illustrate their biochemical and 
hematological disorders, complications, prevention, and treatments. In 
conclusion, this review provides the most recent information on the current 
global pandemic coronavirus infection (COVID-19), which may help the health 
workers and researchers to pursue their studies. 
Keywords: SARS-CoV-2, COVID-19, Pneumonia, Coronavirus, Treatment, 
Prevention 
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 : الملّخـص
 المرض تُسب ب قد التي الت اجـي ة الفيروسات من جديدة ساللة هو (COVID-19) فيروس كورونا المستجد 
ل (SARS-CoV-2) تحديد تـم  . البشر أو الحيوانات في ة   ألو   وتجدر. 0102 ديسمبر أواخر في مر 
 لإلصابة عرضةً  أألكثر هم المزمن االلتهاب المناعة،أو نقص من يعانون الذين المرضى أن   إلى اإلشارة
ديدة  و ،(Pro-inflammatory) مثل  أعراض عليهم تظهر ما وعادة . COVID-19الفيروس بهذا الش 
د   فشل   و الَمنشأ، قلبي   غير رئوي   والتهاب   الدم، تخث ر في وفرط االلتهاب، تفاقم   أعـراضُ  هي  متعد 
، الت نفسي   الفشل ومتالزمة ((ARDS و األعـضاء، ا الحاد   الت دابير تُــعــد    .المفاجئ الموت إلى يؤد ي مم 
ئيسي ة اإلستراتيجي ة هي الوقائي ة  طب ي   دليل    ـ الحالي الوقت في ـ يوجد ال حيث الفيروس؛ هذا انتشار لمنع الر 
ــةً  لذلك، معالجتها؛ أو كورونا فيروس عن الن اتجة العدوى لمنع  والد راسات البحوث من مزيد إلى حاجة   ثَــم 
 ومضاعفاته الفيروس، بهذا اإلصابة عن الن اجمة والد موي ة الحيوي ة كيميائي ةال االضطرابات آلي ة لفهم
م الختام، وفي عالجه. وكيفي ة منه والوقاية ر تُـقـد   المنشوره والبيانات المعلومات أحدث المراجعة هذه وتُـوفـ 
ي   المجال في العاملين تساعد قد والتي ،(COVID-19) الوبائي   الفيروس هذا حول ح   على والباحثين الص 
ة األهداف لتحقيق وأبحاثهم دراساتهم متابعة  .المرجـو 
 المستجد، الوقاية ، العالج كوروونا الت اجـي ة، فيروس : الفيروساتالمفتاحيةالكلمات 
 
Introduction 
By the end of 2019, several patients were diagnosed with pneumonia of unknown 
reasons, epidemiologically associated with the same seafood market in Wuhan, 
Hubei province, central China. This condition caught the attention of the Chinese 
Center for Disease Control and Prevention (CDC), and the WHO launched an 
emergency response immediately, and later the CDC experts identified that the 
pneumonia was caused by a novel coronavirus (NCV). The Chinese government 
had taken great and extraordinary measures to control the outbreak. On January 
30, 2020, the World Health Organization (WHO) designated an outbreak of a 
novel coronavirus not seen before in humans to be a “public health emergency of 
international concern” (PHEIC); this was followed by the declaration of a 
pandemic on March 11, 2020 (WHO, 2020c, Lai et al., 2020). 
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The novel virus was named Wuhan coronavirus or 2019 novel coronavirus 
(2019-nCov) by the Chinese researchers. The International Committee on 
Taxonomy of Viruses (ICTV) named the virus as SARS-CoV-2 and the disease 
as COVID-19. WHO officially named the disease COVID-19. By May 28
th
, 
2020, the pandemic cases were 5,868,922 and 360,476 deaths worldwide with a 
6.14% mortality rate estimated by WHO on May 28
th
, 2020. In Palestine, the 
pandemic confirmed cases were 570 with 4 deaths only. The diseases spread 
extremely very fast as by the end of June within only one month, the cases have 
been nearly doubled as the coronavirus cases by this time were 10,286,435, 
deaths 505,252 (8%), and recovered were 5,583,314. The high incidence rate and 
cases were in the USA (2,638,386), then Brazil (1,345,470), Russia (641,156), 
India, UK, Spain, Peru, Chile, Italy, and Iran respectively. In Palestine by this 
time, at the end of June, the reported cases were increased very sharply by about 
four times, more than 2,200 cases reported. The outbreak of the disease globally 
was continued raising very sharp as by 11
th
 July 2020, the coronaviruses cases 
reported was 12,872,339 and the death cases were 568,312, the increase rate of 
the new cases was ~8% and the rate of death increased by 1.125%; within about 
two weeks period only, which considered high rates. The highest incidences by 
this time in the USA was 3,356,242 reported cases, then Brazil (1,840,812), India 
(854,480), Russia (727,162), and Peru (322,710), etc. as shown in Table-1. In 
terms of the outbreak of the disease, the rank of the countries is changing every 
day, but the USA and Brazil remain and still rank first and second respectively 
for a while. In Palestine by 11
th
 July 2020, the confirmed cases were 6688, and 
the death cases were 36, with an increased rate of 304%, which extremely very 
high and considered the highest worldwide. The highest cases were in Hebron 
Governorate (4620 cases), with about 70% of the total reported cases, as shown 
in the geographical location of confirmed cases (Figure 1). The high outbreak of 
the disease in this region (Hebron Governorate), as 90% of infections have been 
caused by people meeting up with their families or attending wedding parties or 
3
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funerals and failing to follow health recommendations and maintain social 
distancing according to the Palestinian Ministry of Health officials. 
Figure 1 shown Coronavirus disease 2019 (COVID-19) occupied Palestinian 
territory by 11
th
 July 2020, Cumulative confirmed, recovered and death cases, 
confirmed cases per day (from April to July 2020), confirmed cases by gender 
(5
th
 March to 11
th 
July 2020), and confirmed cases by age in Palestine. Some data 
reported were included and some excluded East Jerusalem. 
(http://www.emro.who.int/pse/palestine-news/top-story.html). Table-1 shows 
cases for the top 30 countries including, other information such as daily new 
cases, total death, totally recovered, a total test of each country, etc. While the 
actual and accurate causes and effective treatment of COVID-19 are still 
unknown or unavailable and the number of active cases of the infection is rising 
every day as mentioned, which raises panic and concern on public health 
worldwide. Prevention is still the best strategy to face this pandemic. In this 
review, we summarized the available up to date studies by global researchers 
about COVID-19. Besides, we highlighted the virology, pathology and cell 
targeting, genomic structure and variation, clinical manifestations, transmission, 
epidemiology, ABO blood groups, and pregnancy-relation of COVID-19, animal 
hosts, diagnosis, treatment, and prevention about this virus and the pandemic. 
The disease spread extremely very fast as by 17
th
 November, 2020 (11:15 GMT) 
there were 55,446,791 cases diagnosed; with 4.3 times increase in 4 months only, 
the recovered cases were 38,606,024, and the death cases were 1,334,297, with 
an increase of ~2.35 times in 4 moths too. The highest incidences by this time 
were in the USA with 11,538,280 (~3.44 times increase) reported cases, then 
India (8,874,290, ~104 times increase, which is extremely very high), Brazil 
(5,876,740), France (1,991,233), Russia (1,971,013), Spain (1,521,899), UK 
(1,390,681), Argentina (1,318,384) and Italy (1,205,881). The rank of the 
countries is changing every day, but the USA remain and still rank first for a 
while. While Palestine on 16
th
 November, 2020 (15 GMT) the confirmed cases 
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were 76162, with ~11.4 times increase with in 4 months, which is extremely very 
high. The death cases were 647, and recovered cases in Palestine were 66553 
(~87.5%). With these confirmed cases Palestine ranked 69 among 215 countries 
that have coronavirus. It is worth to mention that Palestine on 13th July 2020 and 
1st July, ranked 85 and 97 respectively; among 215 countries that have 
coronavirus; with one of the highest outbreak rate in the world; compare to 
population number. Within only 4 months period the Palestine rank changed 
from 97 to 69; however, if the outbreak in Palestine remains rising in the same 
rate, Palestine after a short period will be one of the top countries having the 
disease, if real and serious precautions did not apply especially the health 
recommendations, isolation and maintain social distance. The high outbreak of 
the disease in this region (Hebron Governorate) with 12277 confirmed cases 
(~25%), as 90% of infections have been caused by people meeting up with their 
families or attending wedding parties or funerals and failing to follow health 
recommendations and maintain social distancing according to Palestinian 
Ministry of Health officials. While the actual and accurate causes and effective 
treatment of COVID-19 are still unknown or unavailable and the number of 
active cases of the infection is rising every day as mentioned, which rising panic 
and concern on public health worldwide. Prevention is still the best strategy to 
face this pandemic. In addition, these numbers are possibly an underestimate of 
the infected and dead due to limitations of surveillance and testing.  
While the vaccines may potentially prevent infection, they cannot cure the 
disease, but researchers worldwide are working around the clock to find a 
vaccine against SARS-CoV-2. Vaccines typically require years of research and 
testing before reaching the clinic, but scientists are racing to produce a safe and 
effective coronavirus vaccine by next year. Researchers are testing 54 vaccines in 
clinical trials on humans, and at least 87 preclinical vaccines are under active 
investigation in animals. Work began in January with the deciphering of the 
SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, 
and now 12 have reached the final stages of testing. Some of these trials will fail, 
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and others may end without a clear result. But a few vaccines may succeed in 
stimulating the immune system to produce effective antibodies against the virus. 
Moderna develops vaccines based on messenger RNA (mRNA) to produce viral 
proteins in the body. They have yet to bring one to the market. In January, they 
began developing a vaccine for the coronavirus. The vaccine contains genetic 
instructions for building a coronavirus protein, known as spike. When injected 
into cells, the vaccine causes them to make spike proteins, which then get 
released into the body and provoke a response from the immune system. On 
November 9, 2020 New York-based Pfizer and the German company BioNTech 
made history by presenting preliminary data indicating that their coronavirus 
vaccine was over 90 percent effective. It was the first time anyone had found 
such evidence. A week later, Moderna reported similar findings with a similar 
vaccine. On November 16, 2020 Moderna announced that a preliminary analysis 
of the trial indicated that the vaccine was 94.5 percent effective. Out of 95 
participants who got Covid-19, 90 had the placebo and only 5 had the vaccine. 
The results came just a week after Pfizer made a similar announcement about 
their own vaccine, which is also based on an mRNA molecule encoding the spike 
protein. Another promising result from Moderna’s trial was the finding that the 
vaccine appears to protect people from severe disease. Of the 11 volunteers who 
developed severe disease, none were vaccinated. The trial will continue to gather 
more results; Moderna says it plans to submit an application for an Emergency 
Use Authorization in the next few weeks. There are different vaccines are under 
testing by several companies worldwide, either they are in clinical trials or at 
preclinical investigation as mentioned. (The New York times, 2020). 
Methodology 
Literature and guidelines in different databases were collected and summarized. 
Preciously, a literature review using Google Scholar, Medline, PubMed, Web of 
Science, and Science Direct was conducted to identify peer-reviewed published 
articles on SARS-CoV, MERS-CoV, and 2019-nCoV. The initial terms “words” 
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that match with the title or abstract or with the topic including 2019-nCoV, 2019 
novel coronavirus, SARS, CoV-2, COVID-19, coronavirus disease 2019, NCP, 
Novel coronavirus pneumonia were used in searching the databases. Further 
search using the keywords mentioned above, SARS, SARS-CoV, severe acute 
respiratory syndrome, MERS, MERS-CoV, Middle East respiratory syndrome, in 
combinations of with "pike protein, genome, reproductive number, incubation 
period, fatality rate, clinical characteristics, pathology, autopsy, treatment, and 
prevention. Moreover, official documents that have been released by the World 
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World 12,872,339 568,312 7,502,157 4,801,870 58,807 1,651 72.9   
USA 3,356,242 137,414 1,490,702 1,728,126 15,819 10,138 415 41,773,190 331,060,504 
Brazil 1,840,812 71,492 1,213,512 555,808 8,318 8,658 336 4,572,796 212,603,520 
India 854,480 22,718 537,599 294,163 8,944 619 16 11,587,153 1,380,381,949 
Russia 727,162 11,335 501,061 214,766 2,300 4,983 78 23,031,056 145,936,493 
Peru 322,710 11,682 214,152 96,876 1,315 9,784 354 1,904,242 32,983,682 
Chile 312,029 6,881 281,114 24,034 1,999 16,319 360 1,273,627 19,120,870 
Spain 300,988 28,403 N/A N/A 617 6,438 607 5,734,599 46,755,366 
Mexico 295,268 34,730 180,852 79,686 378 2,289 269 723,668 128,969,990 
UK 288,953 44,798 N/A N/A 185 4,256 660 11,782,192 67,896,748 
South 
Africa 
264,184 3,971 127,715 132,498 539 4,453 67 2,108,570 59,328,450 
Iran 257,303 12,829 219,993 24,481 3,359 3,062 153 1,972,207 84,021,254 
Pakistan 248,872 5,197 156,700 86,975 2,118 1,126 24 1,562,638 220,990,656 
Italy 242,827 34,945 194,579 13,303 67 4,016 578 5,900,552 60,458,858 
Saudi 
Arabia 
229,480 2,181 165,396 61,903 2,230 6,589 63 2,226,290 34,827,377 
Turkey 211,981 5,344 193,217 13,420 1,194 2,513 63 3,930,223 84,363,898 
Germany 199,812 9,134 184,500 6,178 278 2,385 109 6,376,054 83,792,278 
Bangladesh 183,795 2,352 93,614 87,829 1 1,116 14 943,524 164,734,934 
France 170,752 30,004 78,388 62,360 496 2,616 460 1,384,633 65,278,075 
Colombia 145,362 5,119 61,186 79,057 875 2,856 101 1,006,093 50,897,758 
Canada 107,347 8,773 71,266 27,308 2,156 2,844 232 3,183,516 37,751,539 
Qatar 103,128 146 98,934 4,048 141 36,729 52 409,199 2,807,805 
Argentina 97,509 1,810 41,408 54,291 688 2,157 40 456,042 45,207,451 
China 83,594 4,634 78,634 326 3 58 3 90,410,000 1,439,323,776 
Egypt 81,158 3,769 23,876 53,513 41 793 37 135,000 102,379,206 
Indonesia 75,699 3,606 35,638 36,455  277 13 1,061,367 273,603,023 
Iraq 75,194 3,055 43,079 29,060 400 1,869 76 671,478 40,241,752 
Sweden 74,898 5,526 N/A N/A 85 7,415 547 600,019 10,101,130 
Ecuador 67,209 5,031 30,107 32,071 308 3,808 285 181,564 17,649,781 
Belarus 64,932 464 55,380 9,088 89 6,872 49 1,134,653 9,449,221 
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Result and Discussion 
Virology 
Coronaviruses (CoVs) are named for the crown-like spikes on their surface 
protruding to the periphery with a diameter of 60-160nm under electron 
microscopy (Shereen et al., 2020, Singhal, 2020, Chavez et al., 2020). They 
belong to the Nidovirales order, which contains Coronaviridae, Arteriviridae, and 
Roniviridae families (Xie and Chen, 2020, Kang et al., 2020). The Coronaviridae 
is composed of a large, single, positive-sense RNA (+ssRNA) genome of 27-32 
kb with a 5'-cap structure and 3'poly-A tail  
which interacts with the nucleoprotein (Shereen et al., 2020, Kang et al., 2020). 
The Coronavirinae is one of two subfamilies in the Coronaviridae family, and the 
other one is the Torovirinae (Kang et al., 2020). The Coronairinae is further 
subdivided into four groups, the alpha, beta, gamma, and delta coronaviruses. 
The groups were labeled by 
phylogenetic clustering (Shereen et al., 2020, Kang et al., 2020). Coronavirus is a 
beta virus that infects vertebrates including humans and is known to cause 
gastrointestinal (GI) and respiratory diseases and sometimes involving important 
organs such as the liver, kidney, heart, and brain (Kang et al., 2020, Chavez et 
al., 2020). 
Before 2019 six CoVs only were identified to cause a human respiratory 
infection; HKU1, HCoV-NL63, HCoV-OC43, and HCoV-229E only induce mild 
upper respiratory disease or sometimes contributed to common clod (Kang et al., 
2020, Yang et al., 2020b), SARS-CoV (Severe Acute Respiratory Syndrome 
Coronavirus) and MERS-CoV (the Middle East Respiratory Syndrome 
Coronavirus) attack lower respiratory tract and always induce severe respiratory 
syndrome (Kang et al., 2020). Genome sequence analysis shows that the 2019 
novel coronavirus (2019-nCoV) has a typical beta coronavirus genome structure 
that includes SARS-CoV and MERS-CoV, it is 82% identical to human SARS-
9
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CoV and 50% to MERS-CoV (Kang et al., 2020, Xie and Chen, 2020). See 
figure 3. It has been the seventh member of coronaviruses that infect humans. 
Moreover, phylogenetic analysis of the viral genome reveals that the coronavirus 
is 89.1% (nucleotide similarity) identical to a group of bat SARS-like 
coronaviruses bat-SL-CoVZXC21 (NCBI accession number MG772934) (Yang 
et al., 2020b, Xie and Chen, 2020). Also, the genome sequence homology of 
2019-nCoV and SARS is about 79%, the 2019-nCoV is closer to the SARS-like 
bat CoVs bat-SL-CoVZC45 (NCBI accession number MG772933) than the 
SARS-CoV by 96% (Wang et al., 2020b, Yang et al., 2020b).  
The genome of coronaviruses is the largest among all RNA viruses; all 
coronaviruses have similar organization and expression of the genome (Kang et 
al., 2020, Shereen et al., 2020). 2019-nCoV has 14 open reading frames (ORFs) 
that encode 27 proteins. ORF1ab and ORF1a are located at the 5' end, both 
encode 15 non-structural proteins (nsps) from nsp1 to nsp10 and from nsp12 to 
nsp16 respectively (Shereen et al., 2020, Kang et al., 2020, Yang et al., 2020b). 
They are followed by four structural proteins, Nucleocapsid (N), Spike (S), 
Envelope (E), and Membrane (M), which are encoded by four other ORFs at the 
3’end (Kang et al., 2020) and eight accessory proteins (3a,3b,p6, 7a, 7b, 8b, 9b 
and orf14) (Yang et al., 2020b) Figure 2 & Figure 3. 
Pathology and Cell Targeting 
The envelope of the virus includes three proteins: M protein binds nucleocapsids 
and enhances viral assembly and budding, E protein is involved in viral 
morphogenesis, release as well as pathogenesis, and S protein contributes to 
homotrimer spikes which recognize the receptor of the cell, thus helping virus 
invade target cell (Kang et al., 2020). See figure 1. They also express other 
polyproteins, nucleoproteins, and membrane proteins, such as RNA polymerase, 
3-chymotrypsin-like protease, papain-like protease, helicase, glycoprotein, and 
accessory proteins (Shereen et al., 2020). 
10
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Figure 2. The electron microscope image depicts the spikes on the outer surface 
of the coronavirus-2 in addition to several protein particles. Eckert A, Higgins D, 
Centers for Disease Control and Prevention. ID# 23313; 2020. 
https://phil.cdc.gov/Details.aspx?pid=23313. Accessed April 6
th
, 2020. (Eckert 
A, 2020). 
The entry mechanism of a coronavirus depends upon cellular proteases which 
include, human airway trypsin-like protease (HAT), cathepsins, and 
transmembrane protease serine 2 (TMPRSS2) that split the spike protein and 
establish further penetration changes, it has been reported that the cellular 
protease MPRSS2 blocks entry of the virus by cleaving the spike protein and 
may constitute a treatment option (Hoffmann et al., 2020). SARS-CoV and 
MERS-CoV recognize exopeptidases while other coronaviruses mostly recognize 
aminopeptidases or carbohydrates as a key receptor for entry to human cells 
(Bertram et al., 2011, Glowacka et al., 2011). 
The spike S protein of 2019-nCov binds to angiotensin-converting enzyme 2 
(ACE2) on target cells, which express ACE2 on their surface, the same 
mechanism as SARS-CoV. See figure 2. In a recent fluorescent study, it was 
confirmed that the 2019-nCoV also uses the same ACE2 cell receptor and 
mechanism for the entry to host cell which is previously used by the SARS-CoV 
(Xu et al., 2020, Gralinski and Menachery, 2020). Zhou et al. confirmed that 
2019-nCoV binds to all ACE2 expressing cells except mice ACE2 cells (Zhou et 
al., 2020). 
11
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Whereas MERS-CoV uses dipeptidyl peptidase 4 (DPP4) as the primary receptor 
(Xie and Chen, 2020, Wu et al., 2020a). 2019-nCoV binds ACE2 with above 10 
folds higher affinity than SARS-CoV, but higher than the threshold required for 
virus infection (Wrapp et al., 2020). Xu et al. concluded that despite the sequence 
diversity between 2019-CoV and SARS-CoV, they share the same 3-D structure 
in the Receptor Binding Domaine (RBD), thus they have similar van der Waals 
and electrostatic properties in the interaction interface of human ACE2 receptors 
(Xu et al., 2020). 
The S protein at metastable prefusion conformation undergoes several structural 
arrangements to combine with the viral membrane of host cells (Su et al., 2016, 
Bosch et al., 2003). The S1 subunit binds to the cell receptor, triggers the 
prefusion trimer's instability, and sheds the S1 subunit, this results in a highly 
stable post-fusion conformation of the S2 subunit (Walls et al., 2017). The S1 
subunit has two different states a “down” conformation and an “up” 
conformation state, which corresponds to a receptor inaccessible state and an 
unstable receptor-accessible state, respectively (Gui et al., 2017, Pallesen et al., 
2017, Walls et al., 2019) Figure 3. 
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Figure 3. The life cycle of SARS-CoV 2. It starts by binding S protein to the 
ACE2 receptor, changing the conformation of S protein facilitating the fusion of 
viral envelope. Then SARS-CoV2 releases its RNA into the host cell, Genome 
RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then 
cleaved into small products by viral proteinases. By discontinuous transcription, 
the polymerase produces a series of sub-genomic mRNA which are translated 
into viral proteins. Viral proteins and genome RNA are assembled into virions in 
the ER and Golgi and then transported outside the cell via vesicles (Shereen et 
al., 2020). 
The respiratory system is the primary target of 2019-nCoV but bioinformatic 
analysis of single-cell transcriptomes datasets of lung, esophagus, gastric, ileum, 
and colon reveal that the digestive system is also a potential route of entry of 
2019-nCoV as ACE2 is highly expressed in absorptive enterocytes from the 
ileum and colon (Zhang et al., 2020). 
The S protein has two regions the S1 and S2, the former has a stronger affinity 
with the receptor binding RBD to bind ACE2 to enter the target cell, but since 
there are changes in the residue in S1 and S2 there are differences in the binding 
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process and the conformation between 2019-nCoV and SARS-CoV, thus 
available monoclonal antibodies do not react with 2019-nCoV (Dong et al., 2020, 
Ren et al., 2020, Wrapp et al., 2020). 
The residues at positions 442, 472, 479, 487, and 491 in S-protein are reported to 
be at receptor complex interface with ACE2, but only TYR491 out of the five are 
preserved in 2019-nCoV (Xie and Chen, 2020). Arg426 is replaced by Asn426 in 
2019-nCoV, so hydrogen bonds are lost which leads to the increased binding free 
energy of 2019-nCoV compared to SARS-CoV (-50.6kcal mol
–1
 vs. -78.6kcal 
mol–1) (Xu et al., 2020, Xie and Chen, 2020). 
It is reported a furin-like cleavage site in the S-protein of 2019-nCoV, which is 
absent in other beta-coronaviruses (Coutard et al., 2020, Wrapp et al., 2020). 
Also, another research team discovered an “RRAR” furin recognition site by an 
insertion in the S1/S2 protease cleavage site in 2019-nCoV, instead of a single 
arginine compared to SARS-CoV (Xie and Chen, 2020, Wrapp et al., 2020). 
Based on current data 2019-nCoV is likely to cause cell pyroptosis in 
lymphocytes through the activation of NLRP3 inflammasome (Yang, 2020). 
Pyroptosis is a novel inflammatory form of programmed cell death. In 2019, it 
was found that SARS-CoV Viroporin 3a triggers the activation of the NLRP3 
inflammasome and the secretion of IL-1β in bone marrow-derived macrophages, 
suggesting SARS-CoV induced cell pyroptosis (Chen et al., 2019). Studies 
reported that patients with 2019-nCoV have increased IL-1β in the serum (Huang 
et al., 2020a). As the increase in IL-1β is an indicator of cell pyroptosis, it is 
suggested that cell pyroptosis is the pathogenesis of 2019-nCoV. Both classical 
and non-classical cell pyroptosis can induce an increase in IL-1β, so it is unclear 
which pathway is involved in 2019-nCoV. 
Genomic Structure and Variation 
The genomic structure of CoVs is 5′-leader-UTR-replicase-S (Spike)–E 
(Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail (Yang et al., 
14
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2020b). In GenBank, there is only one complete 2019-nCoV genome (29870-bp, 
excluding the poly (A) tail) (accession number MN908947) (Phan, 2020). Five 
typical ORFs on the same coding strand were identified, including ORF1ab 
polyprotein (7096-aa), spike glycoprotein (1273-aa), an envelope protein (75-aa), 
membrane protein (222-aa), and nucleocapsid protein (419aa) (Phan, 2020) 
Figure 4. 
Spike glycoprotein (S) consists of S1 and S2 subunits. The S1 subunit contains a 
signal peptide, an N-terminal domain (NTD), and RBD, while the S2 subunit 
includes the conserved fusion peptide (FP), heptad repeat 1 and 2 (HR1 and 
HR2), transmembrane domain (TM), and a cytoplasmic domain (CP) (Dong et 
al., 2020, Delmas and Laude, 1990, Xia et al., 2020). Furthermore, the S2 
subunit of 2019-nCoV is highly conserved and shares 99% similarity with those 
of Bat-SL-CoVZC45, Bat-SL-CoVZC21, and human SARS-CoV (Dong et al., 
2020, Ceraolo and Giorgi, 2020). The E protein helps in virus assembly and 
release (DeDiego et al., 2007, Nieto-Torres et al., 2014). The N protein consists 
of two domains; they bind to the virus RNA genome via different mechanisms 
(Fehr and Perlman, 2015, Chang et al., 2006). 
 
Figure 4. Beta coronaviruses genome organization. The open reading frame 
(ORF) (green box), structural proteins including spike (blue box), envelope 
(maroon box0, membrane (pink box), and nucleocapsid (cyan box). Accessory 
proteins (light gray boxes). The dotted red underlines are the key variations 
between SARS-CoV and SARS-CoV2 (Shereen et al., 2020). 
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Recent studies declared a bat CoVs sequence, RaTG13, with a 92–96% sequence 
identity with the novel virus, confirming that RaTG13 is the closest relative of 
the 2019-nCoV and forms distinct lineage from other SARS-CoVs (Paraskevis et 
al., 2020, Zhou et al., 2020). This rejects the hypothesis of emergence as a result 
of a recombination event which a previous study suggested (Paraskevis et al., 
2020). Despite the high similarities between 2019-nCoV and RaTG13 S, there 
are two distinct differences: one is an “RRAR” furin recognition site formed by 
an insertion residue in the S1/S2 protease cleavage site in SARS-CoV-2, rather 
than the single Arginine in SARS-CoV (Wrapp et al., 2020, Xie and Chen, 2020, 
Li et al., 2003b) the other difference is the presence of 29 variant residues 
between 2019-nCoV and RaTG13 S, 17 of which mapped to the (RBD) (Wrapp 
et al., 2020). 
Coronaviruses of animal origin undergo mutations by evolution and genetic 
recombination either within the same host species or by transmitting from species 
to other, thus resulting in highly pathogenic and deadly viruses to humans (Sabir 
et al., 2016, Su et al., 2016). In 2019-nCoV two mutations were identified and 
may explain the zoonotic transmission. Genomic alignment of 54 SARS-CoV-2 
genomes identified two hotspots of hypervariability at positions 8789 
(synonymous variant) and 28,151 (Ser/Leu change), located in the polyprotein 
and ORF8 genes respectively (Ceraolo and Giorgi, 2020). There is a single 
N501T mutation in SARS-CoV-2’s Spike protein that may have significantly 
enhanced its binding affinity for ACE2 (Wan et al., 2020). 
 
Clinical Manifestation 
Clinical features of COVID-19 are ranging from an asymptomatic state to acute 
respiratory distress syndrome and multi-organ dysfunction (Singhal, 2020). It is 
difficult to distinguish COVID-19 from other viral upper respiratory illnesses due 
to similar symptoms (Wu and McGoogan, 2020). Fever (78.75%) that does not 
alleviate by traditional anti-infective drugs (Huang et al., 2020a), cough 
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(63.75%), dyspnea (37.50%), tiredness, sore throat, myalgia (22.50%), and 
headache (16.25%) are the most common clinical findings (Wu et al., 2020b, 
Jernigan, 2020). In addition to conjunctivitis in some cases (Singhal, 2020). 
Many other symptoms have been reported such as loss of tasting and smelling, 
increased heart rate (more than 100 bpm), and dehydration (Yang et al., 2020b). 
Most patients are asymptomatic or have these mild upper respiratory symptoms 
or non-severe pneumonia (Heymann and Shindo, 2020), and have a good 
prognosis (Kang et al., 2020). Sever cases (13.8%) have dyspnea, oxygen 
saturation less than 93% in ambient air, RR greater than 30 times/min, and 
PaO2/FiO2 less than 300 mm Hg (Wu et al., 2020b). Critical cases (4.7%) have 
severe complicated pneumonia with acute respiratory distress syndrome (17-29% 
of patients) (Huang et al., 2020a), septic shock, and/or multiple organ failure (5% 
of cases) (Cascella et al., 2020) and are with poor prognosis (Kang et al., 2020). 
A recent study showed that SARS‐CoV‐2 might cause liver damage, renal 
damage, and testicular tissue damage (Fan et al., 2020, Chai et al., 2020). While 
the overall case fatality rate is estimated to be 6% (WHO, 2020b). 
Moreover, lymphocytopenia occurs in 72.3 % of cases (Liu et al., 2020) and 
leukopenia in 25% of cases (Sun et al., 2020).  Some patients may also 
experience confusion, nausea, vomiting, rhinorrhea, and pleurisy (Chen et al., 
2020c), and other complications include acute kidney injury, secondary bacterial 
infection, and cardiac injury (Surveillances, 2020). These atypical symptoms are 
more likely in the elderly and immunocompromised (WHO, 2020b). Disease in 
neonates, infants, and children have been also reported to be significantly milder 
than adult (Chavez et al., 2020). 
Incubation Period (how long it takes for symptoms to appear) 
Symptoms of COVID-19 may appear in as few as 2 days or as long as 14 
(estimated ranges vary from 2-10 days, 2-14 days, and 10-14 days, during which 
the virus is contagious but the patient does not display any symptom 
(asymptomatic transmission). 2-14 days represents the current official estimated 
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range for the novel coronavirus COVID-19. However, a case with an incubation 
period of 27 days has been reported by Hubei Province local government on Feb. 
22 (Reuters, Feb. 22, 2020). Also, a case with an incubation period of 19 days 
was observed in a JAMA study of 5 cases published on Feb. 21. (JAMA, Bai Y, 
Yao L, Wei T, et al., 2020) An outlier of a 24 days incubation period had been 
for the first time observed in a Feb. 9 study (Guan WJ, Ni ZY, Hu Y, et al., 2020) 
WHO said at the time that this could reflect a second exposure rather than a long 
incubation period and that it wasn't going to change its recommendations. The 
period can vary greatly among patients. Mean incubation period observed: 3.0 
days (0-24 days range, a study based on 1,324 cases) 5.2 days (4.1-7.0 days 
range, based on 425 cases). Mean incubation period observed in travelers from 
Wuhan: 6.4 days (range from 2.1 to 11.1 days). The interval from the initiation of 
mild symptoms to significant symptom aggravation like breathlessness or ARDS 
ranges from one to twenty days, with a median of seven days (Huang et al., 
2020a). However, this interval can extend to forty days depending on the age of 
the patient and immune system status (Wang et al., 2020c). 
Since the presence of different symptoms that varies among the patients in 
addition to the continuous discovery of new clinical features, WHO is 
continuously monitoring patients and reporting any new symptoms for a full 
understanding of this novel coronavirus (WHO, 2020b). Understanding the 
incubation period is very important for health authorities as it allows them to 
introduce more effective quarantine systems for people suspected of carrying the 
virus, as a way of controlling and hopefully preventing the spread of the virus. 
 
Transmission 
α and β types of coronaviruses can infect mammals, while γ and δ types tend to 
infect birds (Lau et al., 2010, Yin and Wunderink, 2018). Genome sequencing of 
the novel coronavirus has revealed that bats from the Hipposideridae family are 
the natural origin of the virus. Palm civets have been suspected to be the 
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intermediate that disseminates the infection to humans (Yang et al., 2020b). 
Some of the earliest infected patients with COVID-19 in Wuhan had a history of 
contact with a seafood market that suggests animal-to-person viral transmission 
(Lu et al., 2020), then person to person transmission was suggested after the 
infection of a new set of patients who did not have a history of exposure to the 
mentioned market (Nishiura et al., 2020). 
Person To person contact, transmission by touch, and transmission by aerosols 
are the major three ways of transmission of COVID-19 coronaviruses in general 
(WHO, 2020b). Thus, coronaviruses can be transmitted during coughing or 
sneezing by respiratory droplets when propelled up to 3 feet through the air 
followed by the droplets deposition on the mucous membranes of the nose, 
mouth, or eyes of a close person (Malik et al., 2020) also, the virus can be 
transmitted by handshaking and touch of infected surfaces /object (Lu et al., 
2020). Another transmission method is by the transmission of the virus from an 
asymptomatic infected person to other contacts which can be referred to as 
“hidden transmission” (Chan et al., 2020). 
Fecal-oral transmission is suggested as a potential route of transmission after 
several studies that reported gastrointestinal symptoms (2-10% of cases) in 
infected patients and live virus or viral RNA in feces of some patients (Hindson, 
2020, Chen et al., 2020c). The mechanisms by which SARS-CoV-2 affects the 
gastrointestinal tract is still unknown, it’s expected to be by use ACE2 as a 
receptor for the virus since ACE2 is highly expressed in the GIT (Hindson, 
2020). Environmental and enteric studies should be done to inform this route of 
transmission and to check the viability of the virus in the feces and viral 
concentration in the feces and it correlated with the severity of the infection (Yeo 
et al., 2020). Conclusions based on this information, there is evidence that 
human-to-human transmission has occurred among close contacts since the 
middle of December 2019. Considerable efforts to reduce transmission will be 
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required to control outbreaks if similar dynamics apply elsewhere. Measures to 
prevent or reduce transmission should be implemented in populations at risk. 
Epidemiology 
As reported by the WHO Health Emergency Dashboard (April 12, 10 pm GMT), 
1,775,206 confirmed cases of COVID-19 (SARS-CoV-2) worldwide and 
108,544 (6.18%) confirmed deaths since the beginning of the epidemic, in 213 
Countries, areas or territories (WHO, 2020b). In comparison with the previous 
outbreak of coronaviruses SARS (2002) infected 8422 people in China and 31 
other countries and leads to the death of 919 cases (11%), the number of the 
infected persons is very small compared to COVID-19 while the percent of 
deaths is still higher (WHO, 2003). By May 28
th,
 2020, the pandemic cases were 
5,868,922 and 360,476 deaths worldwide with a 6.14% mortality rate estimated 
by WHO on May 28
th
, 2020 in 216 Countries. The diseases spread extremely 
very fast as by the end of June within only one month, the cases have been nearly 
doubled as the coronavirus cases by this time were 10,286,435, deaths 505,252 
(8%), and recovered were 5,583,314. The high incidence rate and cases were in 
the USA (2,638,386), then Brazil (1,345,470), Russia (641,156), India, UK, 
Spain, Peru, Chile, Italy, and Iran respectively. In Palestine by this time, at the 
end of June, the reported cases were increased very sharply by about four times, 
more than 2,200 cases reported. 
A study on 425 infected patients with COVID-19 in china (Feb 2020) showed 
that of which 56% of patients were males and the median age was 59 years (Sun 
et al., 2020, Li et al., 2020). Another large Chinese study reported that 86.6% of 
72,000 patients are of ages ranging from 30-79 with, 81% of them were mild 
cases while 2.3% died (Surveillances, 2020) 2.1% of all cases were pediatric 
cases (0-19 years old). (Khot and Nadkar, 2020) sever and critical cases represent 
only 14.6% (Surveillances, 2020). Severe COVID-19 risk factors are 
immunocompromised cases, advanced age, cancer, and chronic illnesses (Khot 
and Nadkar, 2020). Patients older than 80 years old presented the highest rate of 
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fatality (14.8%). Patients with comorbidities such as cardiovascular illnesses had 
a fatality rate of 10.5% while those without comorbid conditions had a rate of 
fatality less than 1% (Huang et al., 2020a). 
The outbreak of the disease globally was continued raising very sharp as by 11
th
 
July 2020, the coronaviruses cases reported was 12,872,339 and the death cases 
were 568,312, the increase rate of the new cases were ~8% and the rate of death 
increased by 1.125%; within about two weeks period only, which considered 
high rates. The highest incidences were in the USA with 3,356,242 reported 
cases; by this time, then Brazil (1,840,812), India (854,480), Russia (727,162), 
and Peru (322,710), respectively, as shown in Table-1. In terms of the outbreak 
of the disease, the rank of the countries is changing every day, but the USA and 
Brazil remain and still rank first and second respectively for some time. In 
Palestine by 11
th 
July 2020, the confirmed cases were 6688, and the death cases 
were 36, with an increased rate of 304%, which extremely very high and 
considered the highest worldwide. The highest cases were in Hebron 
Governorate (4620 cases), with about 70% of the total reported cases, as shown 
in the geographical location of confirmed cases (Figure 1). The high outbreak of 
the disease in this region (Hebron Governorate), as 90% of infections have been 
caused by people meeting up with their families or attending wedding parties or 
funerals and failing to follow health recommendations and maintain social 
distancing according to the Palestinian Ministry of Health officials. The greatest 
number of new cases and deaths of COVID-19 being reported by 11
th
 July was in 
the USA, Brazil, India, Russia, Peru, Chile, Spain, Mexico, UK, South Africa, 
Iran, Pakistan, Italy, and (WHO, 2020b). These growing numbers of cases were 
due to the person-to-person transmission that has been reported both in and 
outside of China where most initial cases were reported particularly in Hubei 
Province (Wang et al., 2020b) Figure 5 & Table-1. 
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Figure 5: COVID-19 situation update worldwide, as of 11
th
 July 2020 
Association between the ABO Blood Type and COVID-19 
Interestingly, a small study conducted on 2,173 patients infected with SARS-
CoV-2, 206 of them are dead cases, at three hospitals in Wuhan, China, showed 
that blood group A was associated with a higher risk for acquiring the COVID-19 
compared with non-A blood groups, while blood group O was associated with a 
lower risk (Zhao et al., 2020). Previous studies on coronaviruses have shown 
results that are consistent with the findings of this study (Cheng et al., 2005a). 
This justifies the use of the ABO blood type as a biomarker for differential 
susceptibility of COVID-19 (Zhao et al., 2020). 
Although the mechanism behind these findings is still unclear, it’s expected that 
the lack of anti-A antibodies is the reason behind the increased risk of infection 
in persons with A blood group (Trégouët et al., 2009). Thus, the presence of the 
anti-A antibodies can protect non-A blood groups by the inhibition of the 
interaction between the virus and angiotensin‐converting enzyme 2 (ACE2) 
receptor, which was found to be the receptor for SARS‐CoV‐2 (Guillon et al., 
2008, Zhao et al., 2020). This inhibition specifically occurs for the adhesion of S 
protein-expressing cells of SARS-CoV to ACE2-expressing cell lines (Guillon et 
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al., 2008). By the researcher's predictions, SARS-Cov-2 uses ACE2 not only as 
its host receptor but also uses ACE2 more efficiently than the SARS-CoV strain 
in 2003 (Wan et al., 2020). However, further research and studies are needed to 
prove this hypothesis or to explore other mechanisms. 
COVID-19 in Pregnancy 
Data about pregnancy and neonatal infections are limited, although it’s expected 
that pregnant women have a higher risk of severe disease if infected with the 
virus due to the pregnancy-related decreased immunity (Schmid et al., 2020), 
there is no evidence that pregnancy increases the susceptibility to COVID-19 
infection or causes the development of severe pneumonia (Yang et al., 2020a). 
Fortunately, unlike the other viruses (except herpes virus) that have 
hematogenous transmission from mother to fetus when the virus enters the 
placenta from the maternal blood, coronavirus does not follow this mechanism 
(Schwartz, 2020). There are a few reported cases of infection of newborn babies 
infected by person-to-person contact (Qiao, 2020). Moreover, in a recent study 
on six pregnant patients of COVID-19, the study tested samples from cord blood, 
amniotic fluid in addition to breastmilk, and neonatal throat swab, all the samples 
were negative for SARS-CoV-2 (Chen et al., 2020a). In the same study, the 
clinical features of the nine pregnant women with COVID-19 infection were like 
the symptoms of non-pregnant infected adults (Huang et al., 2020a). 
Animal Hosts of COVID-19 
Although researchers are still learning about the novel coronavirus, it’s now 
known that it is zoonotic and, in some situations, can spread from people to 
animals (Peeri et al., 2020). Scientists are working to establish a potential animal 
reservoir for SARS-CoV-2. A recent study in which the susceptibility of animals 
in close contact with humans to SARS-CoV-2 had been investigated found that 
SARS-CoV-2 replicates poorly in chickens, dogs, ducks, and pigs while cats in 
addition to ferrets are permissive to infection (Shi et al 2020). The study 
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experimentally confirmed the susceptibility of cats to airborne infections (Shi et 
al., 2020). According to reported cases and studies cats can infect each other with 
COVID-19 by respiratory droplets. Moreover, the first human-cat transmission 
has been reported in Belgium (WHO, 2020b). Besides, two cases of dogs in 
Hong Kong tested positive for COVID-19, one of them died. And a tiger tested 
positive for the virus after encountering an infected asymptomatic caretaker 
(WHO, 2020b). 
Diagnosis 
Anyone who deals directly with a person who is confirmed to be infected with 
the virus must isolate himself from others until the tests are performed. Most 
patients with mild cases of COVID-19 have had a fever with and/or symptoms of 
acute respiratory illness like cough and difficulty in breathing (CDC, 2020 -d). 
Patients with these symptoms must ask the nearest health center specialized for 
the examination of COVID-19 to make the test. Patients must wear facemask and 
gloves before any interaction with anyone and place in a private room isolated 
from another person which is an airborne infection isolated room (CDC, 2020b, 
Wax and Christian, 2020). Only health care professionals can enter this room 
with fully protected and isolated clothes. 
Reverse transcription-polymerase chain reaction (RT-PCR) was used for the 
determination of COVID-19. Specific diagnosis is by specific molecular tests on 
respiratory samples (throat swab, nasopharyngeal swab, sputum, endotracheal 
aspirates, and bronchoalveolar lavage). Also, it can be detected in the stool and 
from blood in severe cases (CDC, 2020a). Specimens for virus detection should 
reach the laboratory as soon as possible after collection with Correct handling 
during transportation. And storage in the lab at 2-8°C (WHO, 2020b). There are 
low data available about the sensitivity and specificity for the test, but false 
negatives results may be seen in asymptomatic patients and on the patients in the 
early stage of the illness so they must be continued in isolation until confirmed 
the positive and negative results (CDC, 2020e). Others may have the symptoms 
24
Hebron University Research Journal-A (Natural Sciences) - (???? ????? ?????? ??????- ? (?????? ????????, Vol. 9 [2020], Iss. 1, Art. 4
https://digitalcommons.aaru.edu.jo/hujr_a/vol9/iss1/4
Hejaz A Hatem, et al., A REVIEW ON CORONA VIRUS …., H.U.R.J, Vol. (9), 2020                               69  
                                
of this virus but with negative results so they don't have the disease (CDC, 
2020c). 
Inflammatory factors are often increased in severe and critical patients. Patients 
in the early stage of the disease have normal or decreased in the total number of 
leukocytes in peripheral blood and peripheral blood lymphocytes due to 
weakness in the immune system. Some patients show increases in muscle 
enzymes, liver enzymes, and myoglobin. Like Troponin which may be elevated 
in patients with cardiac involvement so it must be in high consideration for 
patients with suspected myocardial infarction or heart failure (Zaman et al., 
2020). Other signs are C-reactive protein (CRP) and erythrocyte sedimentation 
rate (ESR) are increased in most patients. In severe cases, patients have higher 
plasma levels of IL-2, IL-7, IL-10, G-SCF, IP-10, MCP-1, MIP-1α, TNFα, D-
dimer level, and Prothrombin time. In Guan's study, severe cases had more 
prominent laboratory abnormalities so 82.1%, 36.2%, and 33.7% of the patients 
had lymphopenia, thrombocytopenia, and leukopenia, respectively Compared 
with non-severe cases (Guan et al., 2020) Lymphocytopenia can occur in up to 
80% of patients,  a lymphocyte count <1000 has (Wang et al., 2020a). 
Ultrasound may help diagnose coronavirus because it is cheap and reliable and 
can be used more than once, but it does not help to see the deeper lesions present 
in the lung. However, Patients with COVID-19 have an irregular/thickened 
pleural line, scattered/confluent B lines, and consolidation of various sizes and 
other abnormalities on the lung in various zones especially in the middle and 
outer zones (Zhang et al., 2020). A study of 99 COVID-19 patients found 14% 
had mottling and ground-glass opacities, 25% had unilateral pneumonia and 75% 
of patients had bilateral pneumonia, on chest X-ray and CT imaging (Chen et al., 
2020c). In another study in Wuhan for a case series of patients with COVID-19, 
100% had chest CT findings consistent with pneumonia (Huang et al., 2020a). 
Many suspected cases with negative results of COVID-19 have abnormal CT 
scans; many of them had positive tests on repeat testing (Huang et al., 2020b). 
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Treatment 
As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to 
reduce transmission via standard public health interventions based on isolation of 
cases and tracing of contacts. This contributes to reducing the size of the 
outbreak but cannot control the outbreak (Hellewell et al., 2020). Other 
interventions that were recommended to reduce the outbreak include 
strengthening emergency departments, application of strict hygiene measures for 
the prevention and control of infection, and avoidance of close contact with 
patients suffering from respiratory tract infections (Wu and McGoogan, 2020). 
Efforts are being made to find drugs and vaccines that act against SARS-CoV-2 
to control the outbreak of the virus. Supportive care is the main strategy for 
treatment, preferably with paracetamol for fever. Maintenance of hydration and 
nutrition is also required. Up to 76% of patients with COVID-19 require oxygen 
therapy. Some patients require endotracheal intubation such as patients with 
hypoxemic respiratory patients (Alhazzani et al., 2020). Other patients require 
oxygen supplementation to maintain oxygen saturation between 90%-96% 
(WHO, 2020a). For patients who do not improve with oxygen therapy, a high-
flow nasal cannula (HFNC) is recommended (Alhazzani et al., 2020). 
Many antivirals are being under clinical trials to find drugs that are effective 
against the virus. According to the National Health Commission (NHC) of the 
People’s Republic of China for tentative treatment of COVID-19, several 
antivirals are recommended including, IFN-α, lopinavir/ritonavir, and ribavirin 
treatment of COVID-19. Chloroquine phosphate and arbidol are also 
recommended (NHC, 2020). 
INF-α is a broad-spectrum antiviral that is usually used to treat hepatitis. It 
inhibits the replication of SARS-CoV and MERS-CoV (Falzarano et al., 2013a). 
It is also used in combination therapy with other antivirals such as Ribavirin and 
lopinavir/ritonavir (Arabi et al., 2020). Lopinavir/ritonavir is a protease inhibitor 
that is used for the treatment of HIV (Meynard et al., 2018). Lopinavir works by 
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inhibiting the decomposition of gag-pol protein, while ritonavir works by 
inhibiting the decomposition of gag-pol protein precursor and inhibiting lopinavir 
metabolism, thus increasing its concentration (van der Laan et al., 2018). It was 
found that lopinavir/ritonavir has anti-SARS-CoV and MERS-CoV activity in 
vitro (Chan et al., 2015). In South Korea, an infected patient with COVID-19 
received lopinavir/ritonavir. After eight days of admission, symptoms improved 
and coronavirus load began to decrease until no longer it’s detectable (Lim et al., 
2020). 
Ribavirin is a nucleoside analog with broad-spectrum antiviral activity. It works 
by inhibiting the RNA synthesis of viruses. It has been used to treat HCV and 
RSV (Brown et al., 2019). Ribavirin is usually used in combination therapy to 
treat MERS-CoV and HCoV-OC43. Ribavirin and INF-α combination therapy 
are efficient in treating MERS-CoV (Shen et al., 2016). However, ribavirin side 
effects like anemia limited its use (Falzarano et al., 2013b). A study compared 
ribavirin and lopinavir/ritonavir in treating severe acute respiratory syndrome 
(SARS). Patients treated with lopinavir/ritonavir had a lower risk of acute 
respiratory distress syndrome and death (Chu et al., 2004). Ribavirin still needs 
more studies to determine whether it is effective in treating COVID-19 or not. 
Remdesivir is another nucleoside analog with antiviral activity. It has activity 
against RNA viruses such as Ebola, Marburg, and Nipa viruses (Lo et al., 2017). 
Remdesivir showed activity against MERS-CoV in animal experiments. 
Remdesivir reduced the viral load in lung tissue in mice affected with MERS-
CoV and improved lung function (Sheahan et al., 2020). A randomized, placebo-
controlled, double-blind, multicenter, phase III clinical trial is now being made to 
study the efficacy and safety of Remdesivir in patients with COVID-19. This 
clinical study was launched on February 5, 2020, in China and it’s supposed to 
conclude by the end of April. Patients received an initial dose of 200 mg of 
Remdesivir and 100 mg subsequent dose for 9 days via IV infusions. The control 
group patients received the same dose of placebo. It was found that this dose 
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regimen of intravenous remdesivir was adequately tolerated but did not provide 
significant clinical or antiviral effects in seriously ill patients with COVID-19. 
Studies with larger sample sizes will continue to understand the effect of 
remdesivir on COVID-19. Furthermore, strategies to enhance the antiviral 
potency of remdesivir (eg, higher-dose regimens, combination with other 
antivirals, or SARS-CoV-2 neutralizing antibodies) and to mitigate 
immunopathological host responses contributing to COVID-19 severity (eg, 
inhibitors of IL-6, IL-1, or TNFα) require rigorous study in patients with severe 
COVID-19. 
Hydroxychloroquine is a drug used to treat malaria and autoimmune diseases 
such as lupus and rheumatoid arthritis. Hydroxychloroquine has been 
demonstrated to affect SARS-CoV-2 (Yao et al., 2020). A recent study showed 
the efficacy of hydroxychloroquine in reducing viral nasopharyngeal carriage of 
SARS-CoV-2 in COVID-19 patients in an average of three to six days only 
(Gautret et al., 2020). Azithromycin has been recommended to use with 
hydroxychloroquine to give a synergistic effect in treating COVID-19. 
Azithromycin has been shown to prevent severe respiratory tract infections and 
has activity against Ebola and Zika viruses (Bosseboeuf et al., 2018). 
Arbidol is an antiviral used to treat the influenza virus. A study found that 
Arbidol can inhibit SARS-CoV-2 in vitro. Another antiviral that may have anti-
SARS-CoV-2 activity is Favipiravir. Favipiravir is an RNA-dependent RNA 
polymerase (RdRP) inhibitor. It has anti-influenza activity and it can block the 
replication of filo-, alpha-, arena-, and other RNA viruses (Delang et al., 2018). 
When entering the cells, Favipiravir is converted to its active form Favipiravir-
RTP and it is recognized as a substrate by viral RNA polymerase, thus inhibiting 
its activity (Furuta et al., 2017). Therefore, Favipiravir may be effective against 
SARS-CoV-2 (Table 2). 
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Table 1. Antivirals included in the NHC guidelines (version 6) 




IFN-α 5 million U or equivalent dose 
each time, 2 times/day 




200 mg/50 mg/capsule, 2 
capsules each time, 2 times/day 
Oral  No more than 
10 days 
Ribavirin 500 mg each time, 2 to 3 
times/day in combination with 
IFN-α or lopinavir/ritonavir 
Intravenous 
infusion 




500 mg (300 mg for 
chloroquine) each time, 2 
times/day 
Oral  No more than 
10 days 
Arbidol 200 mg each time, 3 times/day  Oral  No more than 
10 days 
 
Convalescent plasma therapy is another treatment that is now under investigation 
for its efficacy against the SARS-CoV-2 virus. The use of convalescent plasma 
was recommended as an empirical therapy during the outbreak of the Ebola 
virus. It was also recommended as a protocol for the treatment of MERS-CoV in 
2015 (Chen et al., 2020b). Viremia usually peaks in the first week and a potential 
immune response is likely to be developed in the second weak where serum 
cytokines increase above the normal range (Cheng et al., 2005a). Some studies 
found that convalescent plasma might suppress viremia (Schoofs et al., 2016). 
Another study found that convalescent plasma could reduce serum cytokine 
response (Hung et al., 2011). This indicates that convalescent therapy is only 
effective in the early stages of the disease (Cheng et al., 2005b). The therapeutic 
effect of convalescent plasma is dependent upon the level of SARS-CoV-2 
neutralizing antibody titer (NAT). IgG immunoglobulin began to increase in the 
third week of onset, and peaks at the twelfth weak (Li et al., 2003a). One study 
found that convalescent plasma with NAT ≥ 1:16 reduced the mortality of 
influenza (Hung et al., 2011). Thus, it is better to take plasma from patients who 
have recovered and are at week 12 of onset with a NAT level of ≥ 1:16. 
Furthermore, it also needs more studies to prove its effectiveness. 
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Prevention 
There is no proven treatment for coronavirus, so prevention is very important. 
Because of the characteristics of this virus, as it has a long incubation period, the 
infection can be transmitted to many people before symptoms appear, so 
preventive measures are very necessary. 
The greatest danger is the transmission of the virus to a healthcare worker as the 
virus has passed on to many of them, however, it is very important to follow a 
basic protocol to protect them and prevent the transmission of the disease to them 
and others by them (Chang et al., 2020). Those who deal with patients directly 
are isolated from others and do not deal with ordinary patients. The rooms and 
surfaces and equipment should undergo regular decontamination. 
To reduce the spread of the disease in geographical areas, each country 
quarantines travelers and people who dealt with the injured for 14 days to ensure 
that they are free of the virus and prevent its spread (Gostic et al., 2015). 
As for society, the best ways to prevent coronavirus and other viruses are 
necessary to move away from crowded places, leave a safe distance between 
others and follow a healthy lifestyle that is mainly based on maintaining personal 
hygiene, eating healthy foods, good ventilation, sunlight penetration on all 
surfaces, adequate rest, using health masks and using sterilizers on an ongoing 
every 15-20min (Gostic et al., 2015, Simpson et al., 2015, Yoshikawa and High, 
2001). People who already have a vitamin C deficiency are more likely and at 
risk to become infected with the virus (Nonnecke et al., 2014). So vitamin C 
supplementation is very important for prevention according to many studies 
(Hemilä, 1997). Every year an estimated 290,000 to 650,000 people die in the 
world due to complications from seasonal influenza (flu) viruses. There are about 
795 to 1,781 deaths per day due to the seasonal flu. SARS (November 2002 to 
July 2003). The coronavirus that originated from Beijing, China, spread to 
different countries and resulted in more than ten and a half million people 
infected with more than half-million deaths (fatality rate of 8%, by end of June 
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2020). Considering that SARS ended up infecting 5,237 people in mainland 
China, Wuhan Coronavirus surpassed SARS on January 29, 2020, when Chinese 
officials confirmed 5,974 cases of the novel coronavirus (2019-nCoV). One day 
later, on January 30, 2020, the novel coronavirus cases surpassed even the 8,096 
cases worldwide which were the final SARS count in 2003, and now by the end 
of June 2020 coronavirus exceed SARS by millions as mentioned. 
Conclusion 
Coronavirus disease 2019 (COVID-19) has affected more than twelve million 
people worldwide until today in 216 countries. Symptoms of this virus may vary 
from mild symptoms such as fever and cough to severe symptoms in some 
patients such as a proinflammatory and hypercoagulable state, in addition to non-
cardiac pneumonia, multi-organ failure, and ARDS. Supportive treatment is still 
the main strategy in treating this disease since there is no evidence that current 
medicine can prevent or cure the infection resulting from coronavirus. Isolating 
patients and other preventive measures are now the way in reducing the outbreak 
of this virus infection. 
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